Introduction
Chloramphenicol has long been regarded as the treatment of choice for typhoid fever. Our policy of continuing chloramphenicol treatment in full dose for 21 days irrespective of the period of temperature response' 2 resulted in low rates of relapse (2-5%) and convalescent carriers (2-30h) . In Durban, however, the response to chloramphenicol recently has not been as satisfactory as formerly, despite the fact that we have not encountered resistant strains of Salmonella typhi in this area. From elsewhere there are reports on the emergence of strains of S typhi resistant to chloramphenicol,3-8 and this has highlighted the need for an alternative drug for typhoid fever.
We have recently compared amoxycillin and chloramphenicol in a randomised trial in 200 children with typhoid. 9 We found that both the relapse and the carrier rate in the 100 children treated with chloramphenicol was 5%. Only 2% relapsed after amoxycillin, and there were no carriers among those initially treated with this drug. Amoxycillin was also found to be significantly better than chloramphenicol with regard to clinical and temperature response. In a study in adults10 with typhoid fever from the same endemic areas amoxycillin produced satisfactory results.
Since the completion of the first therapeutic trial, a further 155 children with proved typhoid have been studied. This paper reports the outcome in these patients.
Patients and methods
The 155 African children were not randomly allotted to treatment with either amoxycillin or chloramphenicol. Because of the findings in the previous randomised trial of 200 Outcome-All patients in both groups recovered. In group 1 no relapses occurred and no children became carriers. In group 2 one relapse occurred with reisolation of S typhi from the blood 19, 20, and 22 days after treatment stopped. This child responded satisfactorily to a course of amoxycillin. There were six, temporary convalescent carriers in group 2. After treatment stools were positive in four, urine in one, and both stool and urine in one. These six received a full 21-day course of amoxycillin. Thereafter all cultures remained negative over a long period of observation. Two further patients in group 2 failed to respond to chloramphenicol: they remained ill and febrile. Repeat blood cultures were positive on days 5, 13, 14, and 17 in one child and on days 10 and 16 in the other. Treatment was changed to amoxycillin and both responded promptly and recovered completely.
Phage typing-The predominant strain was A (88%). There was one example each of types 42 and 46, and 10 of degraded Vi. Seven were not typable.
In-vitro sensitivity-The S typhi strains recovered from all patients before treatment were sensitive to both amoxycillin and chloramphenicol in disc diffusion. Some strains were also subjected to minimum inhibitory concentration tests, which showed them to be sensitive. The organisms reisolated during treatment and from the one patient who relapsed and the six carriers in group 2 were still sensitive to both drugs.
Adverse reactions-After nine days of amoxycillin treatment one child developed a maculoerythematous rash, which was probably a drug reaction. There were no other adverse reactions to either drug.
Discussion
In this trial amoxycillin gave better results than chloramphenicol. Clinical and temperature responses were significantly better than those obtained with chloramphenicol. Bacteriological response was also better. There were no relapses or cases of children becoming carriers after amoxycillin, whereas two children failed to respond to chloramphenicol, one relapsed, and six became carriers after treatment.
This study confirms our earlier findings.9 Amoxycillin has now been used to treat 185 children with proved typhoid fever, and there have been only two relapses (1%). The only case of the carrier state after amoxycillin occurred in a patient in the first study who initially received chloramphenicol and relapsed. After amoxycillin this patient had one positive urine culture. Thus no carriers were encountered among patients initially treated with amoxycillin.
Among 170 patients treated with chloramphenicol in this and the earlier trial two patients failed to respond, one relapsed, and 11 became carriers. This bacteriological failure rate of 11% supports our experience in Durban in the past few years that chloramphenicol is not as effective as formerly.
No correlation could be found between the bacteriological failure of chloramphenicol and length of history, nutritional state, or concurrent disease. There did not seem to be a relation between failures and white blood cell counts. The mean was 6-857 x 109/1 (6857/mm3). At the start of treatment the mean neutrophil count was 68% and that of lymphocytes 27%. Serum protein levels did not seem to be a factor. The mean serum globulin level was 44 g/l. As electrophoretic studies were not routinely performed, however, the y-fraction of the globulins was not known. The strains of organism in this area has not changed and sensitivity to chloramphenicol is constant. There has been no change in the product used, the dose, or length of treatment. The reason why the response to chloramphenicol has become less satisfactory remains obscure.
Reports of treatment of typhoid carriers with amoxycillin cover few cases." 12 So far nine of the 11 children who became carriers after chloramphenicol treatment have been given a single 21-day course of amoxycillin with success. This contrasts favourably with past experience, when ampicillin, in high doses over long periods, sometimes failed. In view of the success in treating these few carriers it seems worth while to evaluate amoxycillin in the management of the asymptomatic carrier state in different areas where typhoid fever is endemic.
Amoxycillin is undoubtedly safe and readily acceptable, and on the evidence of its success in symptomatic typhoid fever may well become the drug of first choice in this disease. 
Introduction
Although typhoid fever is not endemic in Egypt, it is a common cause of pyrexia of undetermined origin in adult Egyptians. This fact is overemphasised by general practitioners, who usually start treating patients with pyrexia of undetermined origin with chloramphenicol before the laboratory tests for the diagnosis of enterica have proved or disproved the presumptive diagnosis of typhoid fever. This, together with the prevailing practice by Maadi Armed Forces Hospital, Cairo, Egypt A M AFIFI, MRcP, FRcP, consultant haematologist M ADNAN, MB, DM, assistant haematologist A A EL GARF, MB, registrar, haematology department many ear, nose, and throat specialists of using chloramphenicol as the drug of choice for upper respiratory tract and ear infections, has resulted in excessive use of chloramphenicol in medical practice in Egypt.
Among the many patients subjected to one or several courses of chloramphenicol some have shown definite but transient haematological toxicity characterised by a delayed clinical onset of moderate depression of bone marrow cellularity and a single reversible cytopenia or pancytopenia. This type of toxicity, described by Best' as intermediate between the irreversible aplasia of delayed onset and the dose-dependent transient erythroid depression, is the commonest form of chloramphenicolinduced blood dyscrasia observed by Egyptian haematologists. It is considered to be an idiosyncratic reaction to chloramphenicol of transient type which leads to a short-lived episode of bone marrow aplasia of either one or more of the three elements of haematopoiesis. In addition to the gradually increasing number of patients belonging to this category, a fixed percentage of Egyptian men suffer from the Mediterranean variety of glucose-6-phosphate dehydrogenase deficiency.2 These patients may develop haemolysis and jaundice with fever, and their haemolysis may be aggravated by the administration of challenging agents such as chloramphenicol to the enzyme deficient red cells.
These two facts prompted us to carry out a clinical trial of an alternative drug that could replace chloramphenicol in the treatment of typhoid fever in these patients. Amoxycillin (D(-)a-amino-p-hydroxybenzylpenicillin trihydrate) 1 g sixhourly was chosen for the trial in view of its safety and its considerably higher serum concentrations than ampicillin.8 Reports have shown the success of amoxycillin in treating typhoid fever in several groups of patients. 46 We believed that running a clinical trial of amoxycillin in the treatment of typhoid fever in these two groups of patients was justifiable.
Patients and methods
Thirty adults suffering from typhoid fever and ranging in age from 16 to 38 years were included in the trial. Eighteen were men suffering from severe Mediterranean glucose-6-phosphate dehydro-
